Amisulpride in Schizophrenic Patients

Inclusion criteria

• Patients diagnosed as schizophrenia or schizophrenic disorder according to DSM-IV
• Patients who need new anti-psychotic drugs or need to change the medication due to aggravations of symptoms or recurrence

Exclusion criteria

• Patients with positive symptoms in whom the disorder does not correspond to schizophrenic criteria. (e.g, schizoaffective disorder)
• Patients hypersensitive to the active ingredient or to other ingredients of the study drug
• Prolactin-dependant tumors, pituitary gland prolactinomas and breast cancer
• Pheochromocytoma or Parkinson's disease
• Pregnancy or breast feeding
• Current or recently withdrawn from drug abuse or alcoholism
• Chronic renal failure and other internal or surgical disease which physician decides will be worsened by trial medication or that will affect the metabolism or effects of the trial medication
• Patients with previous histories and clinical improvement was not seen in spite of treatment with 2 anti-psychotics for over 8 weeks
• Slow heart rate of <55bpm, low blood potassium level, congenital prolongation of the QT interval
• Current treatment with a drug likely to cause markedly slow heart rate(<55bpm), low blood potassium level, slowing of intercardiac condition or prolongation of the QT interval

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.